NCT02047890View on ClinicalTrials.gov

Japanese BAY1000394 Monotherapy Phase I Study

PHASE1CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

May 19, 2014

Primary Completion Date

January 6, 2015

Study Completion Date

July 19, 2018

Conditions

Neoplasms

Interventions

DRUG

BAY1000394 (2.5mg)

BAY1000934 2.5mg twice a day (bid) in a 3 days on and 4 days off schedule. (Cohort 1)

DRUG

BAY1000394 (5mg)

BAY1000934 5mg twice a day (bid) in a 3 days on and 4 days off schedule. (Cohort 2)

Trial Locations (2)

277-8577

Kashiwa

811-1395

Fukuoka

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bayer

INDUSTRY